Table 3.

Survival outcomes by FcγRIIa and FcγRIIIa polymorphisms in the group of patients treated with cetuximab (n = 51)

FcγR SNPs5-y PFS (95% CI)HR (95% CI)P5-y DPFS (95% CI)HR (95% CI)P5-y OS (95% CI)HR (95% CI)P
HH45.5 (16.1–74.9)1.0[0.100]45.5 (16.1–74.9)1.0[0.052]63.6 (35.2–92.0)1.0[0.252]
HR80.0 (64.3–95.7)0.27 (0.08–0.90)0.03283.5 (68.6–98.4)0.21 (0.06–0.74)0.01688.0 (75.3–100)0.28 (0.06–1.27)0.100
RR60.0 (35.3–84.7)0.57 (0.18–1.77)0.33164.3 (39.2–89.4)0.46 (0.14–1.51)0.19872.7 (49.8–95.6)0.66 (0.16–2.67)0.567
HH45.5 (16.1–74.9)1.00.05845.5 (16.1–74.9)1.00.02363.6 (35.2–92.0)1.00.171
HR/RR72.5 (58.6–86.4)0.38 (0.14–1.03)76.4 (62.9–89.9)0.30 (0.11–0.85)82.4 (70.6–94.2)0.42 (0.12–1.45)
VV20.0 (0–55.1)1.0[0.017]33.3 (0–86.7)1.0[0.250]60.0 (17.1–100)1.0[0.271]
VF62.5 (43.1–81.9)0.28 (0.09–0.94)0.03962.5 (43.1–81.9)0.54 (0.12–2.53)0.43874.2 (59.9–88.5)0.43 (0.09–2.16)0.308
FF81.8 (65.7–97.9)0.14 (0.03–0.55)0.00581.8 (65.7–97.9)0.25 (0.05–1.41)0.11786.4 (72.1–100)0.23 (0.04–1.37)0.107
VV20.0 (0–55.1)1.00.00733.3 (0–86.7)1.00.23660.0 (17.1–100)1.00.162
VF/FF71.7 (58.8–84.6)0.21 (0.07–0.66)71.7 (58.8–84.6)0.41 (0.09–1.81)80.0 (68.6–91.8)0.33 (0.07–1.55)
HH and/or VV35.7 (10.6–60.8)1.00.00242.0 (13.9–70.0)1.00.01257.1 (31.2–83.0)1.00.018
R and F78.4 (65.1–91.7)0.22 (0.08–0.57)78.4 (65.1–91.7)0.27 (0.10–0.75)86.4 (75.2–97.6)0.24 (0.07–0.78)